Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029

Clinical Microbiology and Infection

Volumn 21, Issue 1, 2015, Pages 103.e1-103.e6

  Surdo, M ^a   Alteri, C ^a   Puertas, M C ^b   Saccomandi, P ^a   Parrotta, L ^c   Swenson, L ^d   Chapman, D ^e   Costa, G ^c   Artese, A ^c   Balestra, E ^a   Aquaro, S ^f   Alcaro, S ^c   Lewis, M ^g   Clotet, B ^b,h   Harrigan, R ^d   Valdez, H ^e   Svicher, V ^a   Perno, C F ^a   Martinez Picado, J ^b,h,i   Ceccherini Silberstein, F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e PFIZER INC   (United States)

^f UNIVERSITY OF CALABRIA   (Italy)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

ⁱ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Dual mixed virus; HIV; Maraviroc; Phenotypic activity; UDPS

Indexed keywords

MARAVIROC; PLERIXAFOR; URIDINE DIPHOSPHATE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENVELOPE GENE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR DOCKING; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS RECOMBINANT; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MUTATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VIRAL TROPISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; TRIAZOLES; VIRAL TROPISM;

EID: 84926350750     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.08.002     Document Type: Article

References (20)

1. Yi Y., Shaheen F., Collman R.G. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. JVirol 2005, 79:1480-1486.
2. Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H.K., et al. Invivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265.
3. Svicher V., Balestra E., Cento V., Sarmati L., Dori L., Vandenbroucke I., et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc invitro. Antiviral Res 2011, 90:42-53.
4. Symons J., van Lelyveld S.F., Hoepelman A.I., van Ham P.M., de J.D., Wensing A.M., et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. JAntimicrob Chemother 2011, 66:890-895.
5. Toma J., Whitcomb J.M., Petropoulos C.J., Huang W. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 2010, 24:2181-2186.
6. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. NEngl J Med 2008, 359:1429-1441.
7. Surdo M., Balestra E., Saccomandi P., Di S.F., Montano M., Di C.D., et al. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. PLoS One 2013, 8:e68076.
8. Saag M., Goodrich J., Fatkenheuer G., Clotet B., Clumeck N., Sullivan J., et al. Adouble-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. JInfect Dis 2009, 199:1638-1647.
9. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Thielen A., et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011, 53:732-742.
10. Da L.T., Wu Y.D. Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5. JChem Inf Model 2011, 51:359-369.
11. Vandekerckhove L.P., Wensing A.M., Kaiser R., Brun-Vezinet F., Clotet B., De L.A., et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011, 11:394-407.
12. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Jensen M.A., et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. JInfect Dis 2011, 203:237-245.
13. Swenson L.C., Dong W.W., Mo T., Demarest J., Chapman D., Ellery S., et al. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Clin Infect Dis 2013, 56:1659-1666.
14. Chen M., Svicher V., Artese A., Costa G., Alteri C., Ortuso F., et al. Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. Bioinformatics 2013, 29:451-460.
15. Tan Q., Zhu Y., Li J., Chen Z., Han G.W., Kufareva I., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013, 341(6152):1387-1390.
16. Tilton J.C., Wilen C.B., Didigu C.A., Sinha R., Harrison J.E., Agrawal-Gamse C., et al. Amaraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. JVirol 2010, 84:10863-10876.
17. Santoro M.M., Armenia D., Fabeni L., Santoro M., Gori C., Forbici F., et al. The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect 2012, 18:E289-E298.
18. Wilkin T.J., Su Z., Kuritzkes D.R., Hughes M., Flexner C., Gross R., et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44:591-595.
19. Simon B., Grabmeier-Pfistershammer K., Rieger A., Sarcletti M., Schmied B., Puchhammer-Stockl E. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 2010, 24:2051-2058.
20. Verhofstede C., Nijhuis M., Vandekerckhove L. Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS 2012, 7:432-439.